These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17392609)

  • 1. Long QT syndrome under mitotane therapy.
    Pliquett RU; Eichfeld U; Stumvoll M; Koch CA
    J Endocrinol Invest; 2007 Feb; 30(2):167-8. PubMed ID: 17392609
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
    Huang H; Fojo T
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3730-2. PubMed ID: 18842984
    [No Abstract]   [Full Text] [Related]  

  • 3. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.
    Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S
    Therapie; 2015; 70(6):545-6. PubMed ID: 26242497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mitotane in the treatment of adrenal carcinoma].
    Sane T
    Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenal carcinoma.
    Freeman DA
    Curr Ther Endocrinol Metab; 1997; 6():173-5. PubMed ID: 9174731
    [No Abstract]   [Full Text] [Related]  

  • 6. Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.
    Salenave S; Bernard V; Do Cao C; Guignat L; Bachelot A; Leboulleux S; Droumaguet C; Bry-Gauillard H; Pierre P; Crinière L; Santulli P; Touraine P; Chanson P; Schlumberger M; Maiter D; Baudin E; Young J
    Eur J Endocrinol; 2015 Feb; 172(2):141-9. PubMed ID: 25411236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
    Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
    Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
    Reine NJ
    Clin Tech Small Anim Pract; 2007 Feb; 22(1):18-25. PubMed ID: 17542193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma.
    De León DD; Lange BJ; Walterhouse D; Moshang T
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4452-6. PubMed ID: 12364417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
    Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R
    Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center.
    Baudry C; Coste J; Bou Khalil R; Silvera S; Guignat L; Guibourdenche J; Abbas H; Legmann P; Bertagna X; Bertherat J
    Eur J Endocrinol; 2012 Oct; 167(4):473-81. PubMed ID: 22815335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mitotane as possible cause of acute intermittent porphyria].
    von Eyben FE
    Ugeskr Laeger; 2011 Sep; 173(37):2268-9. PubMed ID: 21917227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.
    Terzolo M; Pia A; Berruti A; Osella G; Alì A; Carbone V; Testa E; Dogliotti L; Angeli A
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2234-8. PubMed ID: 10852456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism.
    Clemente M; De Andrés PJ; Arenas C; Melián C; Morales M; Pérez-Alenza MD
    Vet Rec; 2007 Dec; 161(24):805-9. PubMed ID: 18083978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.
    Mayor-Ibarguren A; Roldán-Puchalt MC; Gómez-Fernández C; Albízuri-Prado F; Álvarez-Escola C
    JAMA Dermatol; 2016 Jan; 152(1):109-11. PubMed ID: 26444320
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model.
    Zatelli MC; Gentilin E; Daffara F; Tagliati F; Reimondo G; Carandina G; Ambrosio MR; Terzolo M; Degli Uberti EC
    Endocrinology; 2010 Jun; 151(6):2453-61. PubMed ID: 20392828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism.
    Russo M; Scollo C; Pellegriti G; Cotta OR; Squatrito S; Frasca F; Cannavò S; Gullo D
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):614-9. PubMed ID: 26221968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
    Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.